To construct a novel, non-invasive, accurate, and convenient method to achieve the degree of liver damage is an important general problem in the management of patients with chronic liver disease. The investigators would like to develop non invasive advanced Magnetic Resonance Imaging (MRI) techniques (MR elastography, MRI-PDFF) to assess the degree of liver damage in patients with chronic liver disease. These techniques could reach high diagnostic performance for detection of liver fibrosis, inflammation and liver fat content; and could decrease the number of liver biopsies, which have risks and sample only a small portion of the liver.
Chronic liver disease (including viral hepatitis, alcoholic hepatitis, non alcoholic steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, etc..)
Age range of 18 to 75 years old
Accept systematic antiviral therapy or hormone or ursodesoxycholic acid or supportive liver protection therapy
Age less than 18 years
Unable or unwilling to give informed consent
Contra-indications to MRI
Electrical implants such as cardiac pacemakers or perfusion pumps
Treatment-naive patients had already been diagnosed with chronic hepatic disease before enrollment.Patients with liver disease were enrolled in this study to assess the changes in 3D-MRE and MRI-PDFF parameters before and after antiviral therapy or hormone or ursodesoxycholic acid or supportive liver protection therapy.
Cohort
Prospective
3D-MRE,MRI-PDFF
Device3D-MRE(storage modulus, ., loss modulus and damping ratio \[DR\] for liver inflammation and fibrosis) MRI-PDFF(liver fat content)
the changes of liver stiffness assessed by 3D-MRE before and after treatment.
Liver stiffness regression is defined as the change of 3D MRE shear stiffness larger than 19%
Click on the lead sponsor to view all of their trials.
